Can You Take Vyvanse While Breastfeeding?
Yes, you can take Vyvanse (lisdexamfetamine) while breastfeeding, though breastfeeding is not recommended according to the FDA label, and close infant monitoring is essential if you choose to breastfeed. 1
Understanding the Evidence
The 2024 American Journal of Obstetrics and Gynecology guidelines provide the most current framework for this decision. Since lisdexamfetamine is a prodrug that converts to dextroamphetamine in the body, the safety data for amphetamines applies directly to Vyvanse 2.
What the Guidelines Tell Us
According to the most recent expert consensus:
Amphetamines (including Vyvanse) carry an L3 lactation risk category - meaning they are probably compatible with breastfeeding but require careful monitoring 2
"Breastfeeding does not seem to adversely affect infants" when mothers use therapeutic doses of amphetamines 2
The information applies specifically to prescribed therapeutic use, not illicit amphetamine use 2
FDA Label Position vs. Clinical Guidelines
There's an important divergence here:
The FDA label states "breastfeeding is not recommended during treatment with VYVANSE" due to potential serious cardiovascular reactions, blood pressure increases, growth suppression, and peripheral vasculopathy in infants 1
However, the 2024 clinical guidelines from obstetrics experts indicate that amphetamine use during breastfeeding appears safe with appropriate monitoring 2
This reflects the FDA's conservative regulatory stance versus real-world clinical evidence showing safety with monitoring.
Practical Management Approach
If You Continue Vyvanse While Breastfeeding:
Monitor your infant carefully for: 2
- Irritability
- Insomnia or sleep disturbances
- Feeding difficulties
- Adequate weight gain and developmental milestones
Strategies to Minimize Infant Exposure:
The guidelines recommend: 2
- Consider intermittent use - take Vyvanse only on days when ADHD symptom control is most critical
- Time your doses strategically - take immediately after breastfeeding or pumping to minimize drug concentration in milk at next feeding
- Ensure infants are gaining weight appropriately and meeting developmental milestones
Alternative Considerations:
If you're uncomfortable with amphetamine exposure during breastfeeding:
- Methylphenidate has more reassuring breastfeeding data with relative infant doses <1% and is generally not detected in infant blood 2
- Atomoxetine has minimal transfer into milk (0.19% relative infant dose) though guidelines advise caution due to limited data 2, 3
- Bupropion is an option, particularly if you have co-occurring depression, though it's less effective for ADHD than stimulants 2
The Bottom Line
The consensus from 2024 expert guidelines is that treatment with ADHD medications should not be stopped if required for daily functioning of the breastfeeding person 2. The magnitude of documented risks is very low, and untreated ADHD can significantly impair maternal well-being and functioning during the demanding postpartum period.
Key Clinical Principle:
Maternal mental health and functioning directly impact infant care quality. A mother whose ADHD is well-controlled on Vyvanse may provide better infant care than one struggling with untreated symptoms 2. This risk-benefit calculation favors continuing effective treatment with appropriate infant monitoring.
Common Pitfall to Avoid:
Don't automatically discontinue effective ADHD treatment due to breastfeeding without considering the impact of untreated ADHD on maternal functioning and infant care. The evidence supports continuation with monitoring rather than blanket avoidance.